Asset
SOTROVIMAB
VIR BIOTECHNOLOGY INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04988152 | phase1 | completed | 2021-07-06 | 2021-09-02 | Vir Biotechnology, Inc. | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants |
| NCT04913675 | phase3 | terminated | 2021-06-10 | 2022-07-19 | Vir Biotechnology, Inc. | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. |
| NCT05280717 | phase1 | terminated | 2022-03-28 | 2023-04-05 | Vir Biotechnology, Inc. | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) |
| NCT04779879 | phase2 | completed | 2021-02-18 | 2021-08-20 | Vir Biotechnology, Inc. | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 |
| NCT04545060 | phase2_3 | completed | 2020-08-27 | 2021-04-08 | Vir Biotechnology, Inc. | VIR-7831 for the Early Treatment of COVID-19 in Outpatients |
FDA applications (0)
This company has no applications containing this asset.